What is HC Wainwright’s Estimate for ACAD FY2026 Earnings?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at HC Wainwright raised their FY2026 EPS estimates for shares of ACADIA Pharmaceuticals in a research note issued on Wednesday, August 5th. HC Wainwright analyst A. Ghosh now forecasts that the biopharmaceutical company will post earnings per share of $0.56 for the year, up from their prior estimate of $0.37. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.40 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ FY2028 earnings at $2.95 EPS, FY2029 earnings at $3.28 EPS and FY2030 earnings at $3.42 EPS.

Other equities analysts have also recently issued research reports about the company. Bank of America reissued a “buy” rating and set a $14.50 price objective on shares of ACADIA Pharmaceuticals in a research report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $37.00 price target on shares of ACADIA Pharmaceuticals in a research report on Monday, June 29th. Citizens Jmp upped their price target on ACADIA Pharmaceuticals from $35.00 to $36.00 and gave the stock a “market outperform” rating in a report on Wednesday. Oppenheimer increased their price objective on ACADIA Pharmaceuticals from $23.00 to $25.00 and gave the company a “market perform” rating in a research report on Wednesday. Finally, BMO Capital Markets raised their price objective on shares of ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 21st. Fourteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.44.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ:ACAD opened at $28.45 on Friday. The stock’s 50-day moving average is $24.24 and its 200-day moving average is $23.23. The company has a market cap of $4.87 billion, a P/E ratio of 12.82, a P/E/G ratio of 19.47 and a beta of 0.81. ACADIA Pharmaceuticals has a 52-week low of $19.69 and a 52-week high of $29.48.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.11. ACADIA Pharmaceuticals had a net margin of 33.42% and a return on equity of 9.03%. The firm had revenue of $308.00 million during the quarter, compared to analyst estimates of $296.55 million. During the same quarter in the previous year, the business earned $0.16 EPS. The business’s revenue was up 16.4% on a year-over-year basis.

Institutional Trading of ACADIA Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Farther Finance Advisors LLC lifted its position in ACADIA Pharmaceuticals by 67.5% in the fourth quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 386 shares during the period. Meeder Asset Management Inc. bought a new stake in ACADIA Pharmaceuticals in the 4th quarter valued at $26,000. Transamerica Financial Advisors LLC increased its holdings in ACADIA Pharmaceuticals by 304.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 1,005 shares during the period. Federated Hermes Inc. raised its stake in shares of ACADIA Pharmaceuticals by 277.5% in the 4th quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 1,185 shares in the last quarter. Finally, Leonteq Securities AG acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at $52,000. 96.71% of the stock is currently owned by institutional investors.

Insider Activity

In other ACADIA Pharmaceuticals news, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the company’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $26.13, for a total value of $432,660.54. Following the completion of the transaction, the executive vice president owned 18,994 shares of the company’s stock, valued at $496,313.22. This represents a 46.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider James Kihara sold 5,401 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total value of $114,393.18. Following the completion of the sale, the insider owned 24,509 shares of the company’s stock, valued at $519,100.62. This represents a 18.06% decrease in their position. The SEC filing for this sale provides additional information. 26.20% of the stock is currently owned by company insiders.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: ACADIA beat second-quarter earnings and revenue estimates, driven by strong sales of Daybue and Nuplazid. The company also raised its 2026 revenue outlook, providing evidence of continued commercial momentum. ACAD Q2 Earnings and Revenues Beat, 2026 View Raised on Product Sales
• Positive Sentiment: Citizens JMP raised its price target from $35 to $36 and maintained a “market outperform” rating, implying additional upside from the stock’s referenced price level. Citizens JMP Raises ACADIA Price Target
• Positive Sentiment: Rising earnings estimates are providing another potential catalyst. Zacks said recent estimate revisions indicate ACADIA’s shares could continue moving higher, while HC Wainwright raised its Q3 2026 EPS forecast to $0.15 from $0.13 and its FY2027 forecast to $1.89 from $1.70. Can Acadia Run Higher on Rising Earnings Estimates?
• Neutral Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate to $0.20 from $0.21 but retained a “Hold” rating. The mixed revisions suggest improving longer-term expectations but limited near-term conviction. HC Wainwright ACADIA Estimates
• Positive Sentiment: Recent earnings-call materials and coverage highlighted the second-quarter results and product performance, reinforcing the market’s focus on ACADIA’s revenue growth and profitability trajectory. ACADIA Q2 2026 Earnings Call Transcript

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.